Analysts Turn More Bullish on Guardant Health, Inc. (GH) as 2026 Growth Catalysts Build

We recently compiled a list of the Top 10 Oncology Stocks to Buy Now. Guardant Health, Inc. is placed fifth on our list among the best cancer stocks.

TheFly reported on January 9 that Stifel increased its price target on GH to $120 from $100 while maintaining a Buy rating. The firm anticipates strong volume and average selling price growth in 2026, with publication and reimbursement events that it claims will keep investors interested.

Similarly, on the same day, Mizuho raised its price target on Guardant Health, Inc. (NASDAQ:GH) to $135 from $120 while maintaining an Outperform rating. Additionally, the firm revised its models for the diagnostics and medical device sectors.

Guardant Health, Inc. (NASDAQ:GH) is a precision oncology company focused on developing non-invasive liquid biopsy tests for cancer detection, treatment selection, and disease monitoring. Its flagship products, including Guardant360 and Guardant Shield, enable early detection, biomarker profiling, and real-time monitoring, supporting personalized cancer care.

While we acknowledge the potential of GH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.